Hepatology

Phase II ELMWOOD trial shows elafibranor is well tolerated and improves liver biochemistry and pruritus in primary sclerosing cholangitis, supporting further trials.

A phase 2 trial finds tinengotinib demonstrates anti-tumour activity in previously treated advanced cholangiocarcinoma with FGFR alterations.

A new multinational study reports that rifaximin use in cirrhosis and hepatic encephalopathy is linked to significantly higher risks of antimicrobial resistance and severe infections.

Large PBC cohort shows current liver stiffness measurement >10 kPa predicts hepatic decompensation, outperforming biochemical response or LSM trajectory.

New research confirms the GOLDEN model reliably predicts HBsAg loss in interferon-treated chronic hepatitis B patients, supporting more personalized treatment strategies.

Bioinformatics work identifies FAM72A–D as powerful prognostic markers in liver cancer and unveils a compact FAM72 risk score that outperforms existing gene models.

Silencing S100A11 protects against steatosis, inflammation and fibrosis in murine MASH, uncovering HK2 as a key metabolic driver and potential therapeutic target.

High-dose aluminum adjuvant Imject Alum induces immune-mediated liver inflammation and fibrosis in mice, offering a new preclinical model that mirrors human cirrhosis biology.